Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22712506 | 0.86 | KDM4E (0.40) | KDM4EGABRA5DGAT1ALDH1A1EPHX2 | |
| SCHEMBL1403884 | 0.83 | KDM4E (0.43) | KDM4EGABRA5DGAT1ALDH1A1GBA1 | |
| SCHEMBL9935814 | 0.81 | PIM1 (0.39) | PIM1EPHX2VDRMAPT | |
| SCHEMBL9935812 | 0.80 | PIM1 (0.38) | PIM1EPHX2VDRMAPT | |
| SCHEMBL19783022 | 0.77 | EDNRB (0.33) | PIM1ALDH1A1VDR | |
| SCHEMBL1284075 | 0.77 | KDM4E (0.42) | KDM4EGABRA5ALDH1A1LSSGBA1 | |
| SCHEMBL456392 | 0.77 | KDM4E (0.46) | KDM4EGABRA5LSSGBA1MAPT | |
| SCHEMBL21395335 | 0.75 | CYP2D6 (0.41) | KDM4EPIM1ALDH1A1VDRMAPT | |
| SCHEMBL3104534 | 0.75 | KDM4E (0.44) | KDM4EGABRA5GBA1MAPT | |
| SCHEMBL256028 | 0.75 | PIK3CD (0.43) | KDM4EGABRA5DGAT1ALDH1A1LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| EP-3891158-A1 | MAP4K4 INHIBITORS | Imperial College of Science, Technology and Medicine (GB) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | KDM4E 1003/4885PIM1 272/4885GABRA5 3873/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | KDM4E 1003/4885PIM1 272/4885GABRA5 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.